The Food and Drug Administration’s (FDA) Oncology Drug Advisory Committee (ODAC) is meeting today to discuss whether the labels for Erbitux (cetuximab) and Vectibix (panitumumab) should include a mention of KRAS testing. The discussion at the meeting will have implications for future development of companion diagnostics. C3 President Carlea Bauman will be testifying during the public comment section: Read the rest of this entry »